ClinicalTrials.gg
Not yet recruitingNCT06905314Updated Apr 1, 2025

A Single Ascending Dose of HRS-4029 in Healthy Subjects

A Phase 1 interventional study of HRS-4029 and Placebo in Acute Ischemic Stroke, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 750 studies in Ischemic Stroke with a site in China — 377 open to participants now, 396 under way, 76 of them phase 3. Ischemic Stroke · China.

Planned enrollment
497th of 563
55 · median 266
Started
2025
with 106 others
Phase 1
28 of 750
10 open now
Primary completion
2025-10
later than 70 of 395 live
Registered
546th of 750
by date

Among the 750 studies in Ischemic Stroke with a site in China, this one is the 497th largest by planned enrollment of the 563 interventional ones that give a count, is one of 107 that started in 2025, is one of 28 in phase 1, reaches primary completion later than 70 of the 395 other live ones, and was the 546th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

377 of the 750 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

372 more — sign in →

All 377 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 750 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 to 55 years.
  2. (BMI) of 19.0 to 28.0 kg/m2 (inclusive).
  3. Agreed to take effective measures during and 3 months after the last dose of the study period.
  4. Understand in detail the content, procedure and possible adverse effects of the trial, and voluntarily sign the written form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Diseases with abnormal clinical manifestations that occurred before screening or are currently occurring and need to be excluded.
  2. Vital signs, physical examination, 12-lead ,or laboratory examination deemed by the investigator .
  3. Subjects with positive tests for infectious diseases.
  4. Female who are pregnant or breastfeeding.
  5. Unable to tolerate venipunctures or have a history of fainting needles and blood.
  6. Historic abuse of alcoholic beverages
  7. Smoke ≥5 cigarettes per day within 3 months prior to the study
  8. History of drug abuse.
  9. Other reasons that the investigator consider it inappropriate to participate in the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Group A

    Drug: HRS-4029 Subject will receive HRS-4029 at dose level 1. Drug: Placebo Subject will receive placebo at dose level 1.

    Drug: HRS-4029 · Drug: Placebo

  • Experimental
    Group B

    Drug: HRS-4029 Subject will receive HRS-4029 at dose level 2. Drug: Placebo Subject will receive placebo at dose level 2.

    Drug: HRS-4029 · Drug: Placebo

  • Experimental
    Group C

    Drug: HRS-4029 Subject will receive HRS-4029 at dose level 3. Drug: Placebo Subject will receive placebo at dose level 3.

    Drug: HRS-4029 · Drug: Placebo

  • Experimental
    Group D

    Drug: HRS-4029 Subject will receive HRS-4029 at dose level 4. Drug: Placebo Subject will receive placebo at dose level 4.

    Drug: HRS-4029 · Drug: Placebo

  • Experimental
    Group E

    Drug: HRS-4029 Subject will receive HRS-4029 at dose level 5. Drug: Placebo Subject will receive placebo at dose level 5.

    Drug: HRS-4029 · Drug: Placebo

  • Experimental
    Group F

    Drug: HRS-4029 Subject will receive HRS-4029 at dose level 6. Drug: Placebo Subject will receive placebo at dose level 6.

    Drug: HRS-4029 · Drug: Placebo

Interventions

  • DrugHRS-4029

    HRS-4029

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. The incidence and severity of adverse events

    Time frame: From ICF signing date to Day15

Secondary outcomes

  1. Maximum observed concentration of HRS-4029 (Cmax)

    Time frame: 0 hour to 48 hour after administration

  2. Area under the serum concentration time curve (AUC) of HRS-4029

    Time frame: 0 hour to 48 hour after administration

  3. Time to maximum observed concentration (Tmax) of HRS-4029

    Time frame: 0 hour to 48 hour after administration

  4. Half-life (T1/2) of HRS-4029

    Time frame: 0 hour to 48 hour after administration

  5. Clearance (CL) of HRS-4029

    Time frame: 0 hour to 48 hour after administration

  6. Volume of distribution (Vz) of HRS-4029

    Time frame: 0 hour to 48 hour after administration

  7. Number of subjects who developed HRS-4029 antidrug antibodies (ADA)

    Time frame: Baseline to Day15

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Oct 2025, 6 months later.

Of 42 phase 1 interventional studies under Ischemic Stroke, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 1, 2025
StartEst.
Apr 2025
Primary completionEst.
Oct 2025
CompletionEst.
Dec 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06905314
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
Apr 2025 (estimated)
Primary completion
Oct 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 1, 2025

Study contacts

Yuanyuan Huang
Contact
yuanyuan.huang@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion